Metabolic Syndrome: Clinical and Policy Implications of the New Silent Killer
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The United States is experiencing its greatest life expectancy ever. Nonetheless, the general health of the US population is far from at an all-time high. An important contributor to the pandemic of cardiovascular disease is that overweight and obesity are also the major determinants of metabolic syndrome, an all too common and all too serious clinical and public health challenge. Clinicians have traditionally evaluated each of the major risk factors contributing to metabolic syndrome on an individual basis. There is evidence, however, that the risk factors are more than additive. The overlap of these factors in each disease state, resulting in increased atherogenic risks, is worth examining as a broader entity rather than separately. While therapeutic lifestyle changes (TLCs) should be strongly recommended, clinicians should not let the perfect be the enemy of the possible. Evidence-based doses of statins, aspirin and angiotensin-converting enzyme inhibitors, or angiotensin II receptor blockers should be prescribed as adjuncts, not alternatives, to TLCs. In fact, there is cogent evidence that the benefits of these pharmacologic therapies may also be at least additive.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Explaining the decrease in U.S. deaths from coronary disease, 1980–2000
Ford, E. S., Ajani, U. A., Croft, J. B., Critchley, J. A., Labarthe, D. R., Kottke, T. E., Giles, W. H., & Capewell, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmsa053935 · Cited by 2,757
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
The Diabetes Prevention Program (DPP)
The Diabetes Prevention Program (DPP) Research Group (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2165 · Cited by 1,938
Prevalence of the metabolic syndrome in the United States, 2003-2012
Aguilar, M., Bhuket, T., Torres, S., Liu, B., & Wong, R. J. (2015) · JAMA · doi:10.1001/jama.2015.4260 · Cited by 1,267
Visceral Adiposity and the Risk of Metabolic Syndrome Across Body Mass Index
Shah, R. V., Murthy, V. L., Abbasi, S. A., Blankstein, R., Kwong, R. Y., Goldfine, A. B., Jerosch-Herold, M., Lima, J. A. C., Ding, J., & Allison, M. A. (2014) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2014.07.017 · Cited by 427 · cited 1×
“With respect to the pathophysiology of metabolic syndrome, visceral fat and its clinically more easily measured correlate of waist circumference are gaining increasing attention as strong predictors of the metabolic syndrome, even independent of body mass index (BMI).(6) Increased interleukin 6 and other inflammatory…”
BackgroundLeft behind: widening disparities for males and females in US county life expectancy, 1985–2010
Wang, H., Schumacher, A. E., Levitz, C. E., Mokdad, A. H., & Murray, C. J. (2013) · Population Health Metrics · doi:10.1186/1478-7954-11-8 · Cited by 147
Arnaboldi, L., & Corsini, A. (2015) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(14)70002-9 · Cited by 55
Leading Avoidable Cause of Premature Deaths Worldwide: Case for Obesity
Hennekens, C. H., & Andreotti, F. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.06.018 · Cited by 52
Self-citationKim, J., Choi, E., Mun, H.-S., Min, P., Yoon, Y. W., Lee, B. K., Hong, B., Rim, S., & Kwon, H. M. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-140 · Cited by 28
Cited by
Song, J., He, Y., Luo, C., Feng, B., Ran, F., Xu, H., Ci, Z., Xu, R., Han, L., & Zhang, D. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105109 · Cited by 303
Monounsaturated Fatty Acids in Obesity-Related Inflammation
Ravaut, G., Légiot, A., Bergeron, K.-F., & Mounier, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010330 · Cited by 249
Wewege, M. A., Thom, J. M., Rye, K.-A., & Parmenter, B. J. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.05.002 · Cited by 210
Blueprint for cancer research: Critical gaps and opportunities
Elmore, L. W., Greer, S. F., Daniels, E. C., Saxe, C. C., Melner, M. H., Krawiec, G. M., Cance, W. G., & Phelps, W. C. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21652 · Cited by 156
The Therapeutic Potential of Plant Polysaccharides in Metabolic Diseases
Wang, X., Chen, X., Tang, Y., Wu, J., Qin, D., Yu, L., Yu, C., Zhou, X., & Wu, A. (2022) · Pharmaceuticals · doi:10.3390/ph15111329 · Cited by 138
Metadata
- Authors
- Sherling, D. H., Perumareddi, P., & Hennekens, C. H.
- Affiliations
- Florida Atlantic University (US)
- Corresponding author
- Sherling, Dawn Harris
- Venue
- Journal of Cardiovascular Pharmacology and Therapeutics
- Publisher
- SAGE Publications
- Published
- 2017-01-09
- Volume
- 22
- Issue
- 4
- Pages
- 365-367
- ISSN
- 1074-2484 (ISSN-L)
- 1940-4034
- OpenAlex
- W2571450722
- Cited by
- 268
- References
- 11
- Citations by year
- 2026: 5 · 2025: 17 · 2024: 24 · 2023: 25 · 2022: 39 · 2021: 50 · 2020: 67 · 2019: 30 · 2018: 7 · 2017: 4
- FWCI
- 23.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Cardiovascular Pharmacology and Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- metabolic syndrome, cardiovascular disease, obesity, overweight, atherogenic risk, therapeutic lifestyle changes, statins, aspirin, ACE inhibitors, angiotensin receptor blockers, pharmacotherapy
- MeSH terms
- Healthy Lifestyle, Diet, Healthy, Animals, Health Status, Humans, Prognosis, Risk Factors, Exercise, Metabolic Syndrome, Risk Reduction Behavior, Protective Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolic Syndrome: Clinical and Policy Implications of the New Silent Killer. https://app.cochat.ai/papers/10.1177/1074248416686187
- The paper
- Sherling, D. H., Perumareddi, P., & Hennekens, C. H. (2017). Metabolic Syndrome: Clinical and Policy Implications of the New Silent Killer. Journal of Cardiovascular Pharmacology and Therapeutics. https://doi.org/10.1177/1074248416686187
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.